Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial

Aymin Delgado-Borrego, Sergio H. Jordan, Betania Negre, David Healey, Wenyu Lin, Yoshitaka Kamegaya, Marielle Christofi, David A. Ludwig, Anna S.F. Lok, Raymond T. Chung

Research output: Contribution to journalArticle

57 Scopus citations

Abstract

Background & Aims: Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established. Methods: We performed a longitudinal study within the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial to evaluate whether suppression of hepatitis C is associated with improvement in IR. Participants had advanced hepatic fibrosis and carried non-3 HCV genotypes (n = 96). Patients underwent 24 weeks of pegylated interferon and ribavirin therapy and were categorized into HCV clearance groups at week 20 on the basis of HCV RNA levels; null responders had <1 log10 decline (n = 38), partial responders had ≥1 log10 decline (n = 37) but detectable HCV RNA, and complete responders had no detectable HCV RNA (n = 21). The primary outcome was change (week 20 minus week 0) in IR by using the homeostasis model assessment (HOMA2-IR). Results: Adjusting only for baseline HOMA2-IR, mean HOMA2-IR differences were -2.23 (complete responders), -0.90 (partial responders), and +0.18 (null responders) (P = .036). The observed differences in mean HOMA2-IR scores were ordered in a linear fashion across response groups (P = .01). The association between HCV clearance and improvement in HOMA2-IR could not be accounted for by adiponectin or tumor necrosis factor-alpha and was independent of potential confounders including age, gender, ethnicity, body mass index, duration of infection, medications used, and fibrosis. Conclusions: HCV suppression correlates with improvement in IR. These data provide further support for a role of HCV in the development of insulin resistance.

Original languageEnglish (US)
Pages (from-to)458-462
Number of pages5
JournalClinical Gastroenterology and Hepatology
Volume8
Issue number5
DOIs
StatePublished - May 1 2010

    Fingerprint

Keywords

  • Adiponectin
  • Cirrhosis
  • HALT-C
  • HOMA
  • Interferon

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Delgado-Borrego, A., Jordan, S. H., Negre, B., Healey, D., Lin, W., Kamegaya, Y., Christofi, M., Ludwig, D. A., Lok, A. S. F., & Chung, R. T. (2010). Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial. Clinical Gastroenterology and Hepatology, 8(5), 458-462. https://doi.org/10.1016/j.cgh.2010.01.022